A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).

Tytuł:: A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).
Autorzy:: Kong X; Integrated Traditional Chinese and Western Medicine Laboratory, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Lu P; State Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Liu C; Department of Pharmaceutical Analysis, School of Chinese Materia Medical, Beijing University of Chinese Medicine, Beijing 102488, P.R. China.
Guo Y; Department of Radiotherapy, Tianjin Hospital, Tianjin 300211, P.R. China.
Yang Y; Integrated Traditional Chinese and Western Medicine Laboratory, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Peng Y; Integrated Traditional Chinese and Western Medicine Laboratory, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Wang F; Integrated Traditional Chinese and Western Medicine Laboratory, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Bo Z; Integrated Traditional Chinese and Western Medicine Laboratory, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Dou X; Integrated Traditional Chinese and Western Medicine Laboratory, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Shi H; Integrated Traditional Chinese and Western Medicine Laboratory, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Meng J; Integrated Traditional Chinese and Western Medicine Laboratory, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
Źródło:: Molecular medicine reports [Mol Med Rep] 2021 May; Vol. 23 (5). Date of Electronic Publication: 2021 Mar 24.
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Original Publication: Athens, Greece : D. A. Spandidos
MeSH Terms:: B7-H1 Antigen/*genetics
Immune Checkpoint Inhibitors/*therapeutic use
Neoplasms/*therapy
Programmed Cell Death 1 Receptor/*genetics
B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/immunology ; Cancer Vaccines/immunology ; Cancer Vaccines/therapeutic use ; Humans ; Immune Checkpoint Inhibitors/immunology ; Immunotherapy/trends ; Neoplasms/genetics ; Neoplasms/immunology ; Oncolytic Virotherapy/trends ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology
References:: Ann Oncol. 2019 Aug 1;30(8):1244-1253. (PMID: 31143921)
Nutrients. 2018 May 19;10(5):. (PMID: 29783752)
JAMA Oncol. 2019 Jul 11;:. (PMID: 31294749)
Clin Dermatol. 2013 Mar-Apr;31(2):191-9. (PMID: 23438382)
N Engl J Med. 2017 Nov 16;377(20):1919-1929. (PMID: 28885881)
J Immunother Cancer. 2020 Feb;8(1):. (PMID: 32102830)
Mol Ther Oncolytics. 2015 Sep 09;2:15014. (PMID: 27119109)
Science. 2021 Feb 5;371(6529):602-609. (PMID: 33303685)
J Clin Oncol. 2015 Sep 1;33(25):2780-8. (PMID: 26014293)
J Immunother Cancer. 2019 Aug 14;7(1):218. (PMID: 31412954)
J Thorac Oncol. 2019 Mar;14(3):553-559. (PMID: 30529597)
Pigment Cell Melanoma Res. 2015 May;28(3):245-53. (PMID: 25477049)
Front Immunol. 2020 Jun 16;11:1185. (PMID: 32612606)
Nat Rev Clin Oncol. 2019 Jun;16(6):341-355. (PMID: 30718843)
JAMA Oncol. 2016 Jan;2(1):15-6. (PMID: 26562503)
Front Chem. 2020 Feb 14;8:1. (PMID: 32117862)
J Immunother Cancer. 2019 Jan 9;7(1):6. (PMID: 30626434)
J Immunother Cancer. 2019 Jun 25;7(1):160. (PMID: 31238970)
Nature. 2019 Jan;565(7741):600-605. (PMID: 30675064)
Immunol Rev. 2017 Mar;276(1):80-96. (PMID: 28258692)
Lancet Respir Med. 2019 May;7(5):387-401. (PMID: 30922878)
Cancer Biol Ther. 2006 Apr;5(4):427-34. (PMID: 16575207)
J Immunother Cancer. 2018 Oct 22;6(1):109. (PMID: 30348216)
Immunotherapy. 2016 Feb;8(2):103-6. (PMID: 26799112)
N Engl J Med. 2018 Nov 22;379(21):2040-2051. (PMID: 30280635)
Nature. 2017 Jul 13;547(7662):217-221. (PMID: 28678778)
Immunol Rev. 2017 Nov;280(1):126-148. (PMID: 29027218)
Sci Transl Med. 2012 Mar 28;4(127):127ra37. (PMID: 22461641)
J Clin Oncol. 2013 Dec 1;31(34):4311-8. (PMID: 24145345)
Nat Rev Clin Oncol. 2016 Aug;13(8):473-86. (PMID: 27141885)
Clin Cancer Res. 2014 Oct 1;20(19):5064-74. (PMID: 24714771)
J Thorac Dis. 2017 Aug;9(8):2560-2571. (PMID: 28932563)
Proc Natl Acad Sci U S A. 2017 Jun 27;114(26):6812-6817. (PMID: 28607091)
Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):81-92. (PMID: 32036006)
Molecules. 2019 Nov 09;24(22):. (PMID: 31717574)
Cancer Immunol Res. 2020 Jul;8(7):883-894. (PMID: 32299915)
Blood. 2009 Aug 20;114(8):1537-44. (PMID: 19423728)
Nat Rev Cancer. 2017 May;17(5):286-301. (PMID: 28338065)
Clin Cancer Res. 2015 Feb 15;21(4):712-20. (PMID: 25524312)
Thorac Cancer. 2019 Apr;10(4):975-979. (PMID: 30864291)
Pharmacol Res. 2018 Aug;134:118-133. (PMID: 29898412)
Curr Top Microbiol Immunol. 2011;350:17-37. (PMID: 21061197)
J Immunother Cancer. 2016 Oct 18;4:59. (PMID: 27777769)
Clin Cancer Res. 2020 Sep 1;26(17):4670-4681. (PMID: 32732224)
Ann Oncol. 2019 May 1;30(5):839-844. (PMID: 30847464)
Neuro Oncol. 2018 Apr 9;20(5):674-686. (PMID: 29106665)
J Clin Invest. 2015 May;125(5):2046-58. (PMID: 25866972)
Sci Immunol. 2019 Aug 9;4(38):. (PMID: 31399492)
Curr Cancer Drug Targets. 2020;20(1):3-18. (PMID: 31729943)
Cell Death Dis. 2018 Oct 10;9(10):1039. (PMID: 30305604)
Oncoimmunology. 2019 Sep 2;8(11):1652539. (PMID: 31646082)
Cancer Sci. 2018 Feb;109(2):264-271. (PMID: 29168596)
Lancet Oncol. 2018 Apr;19(4):521-536. (PMID: 29545095)
ESMO Open. 2019 Jun 12;4(Suppl 3):e000497. (PMID: 31275616)
Immunity. 2019 Jan 15;50(1):181-194.e6. (PMID: 30635236)
Cancer Immunol Immunother. 2008 Aug;57(8):1115-24. (PMID: 18193223)
Oncogene. 2020 Feb;39(7):1429-1444. (PMID: 31659256)
Blood. 2018 Jan 4;131(1):49-57. (PMID: 29118009)
Cell. 2018 Oct 4;175(2):313-326. (PMID: 30290139)
Oncoimmunology. 2020 Mar 12;9(1):1736792. (PMID: 32850194)
Eur J Immunol. 2019 Dec;49(12):2235-2244. (PMID: 31465113)
Nat Commun. 2017 Mar 27;8:14754. (PMID: 28345650)
Oncotarget. 2015 Sep 29;6(29):27359-77. (PMID: 26318293)
Ther Adv Vaccines Immunother. 2018 Feb;6(1):3-17. (PMID: 29998217)
Cancer J. 2018 Jan/Feb;24(1):47-53. (PMID: 29360728)
Nature. 2014 Nov 27;515(7528):563-7. (PMID: 25428504)
ACS Nano. 2019 Nov 26;13(11):13127-13135. (PMID: 31710460)
Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):879-80. (PMID: 23078897)
JAMA Oncol. 2020 Mar 1;6(3):375-384. (PMID: 31876895)
Clin Cancer Res. 2017 Sep 15;23(18):5349-5357. (PMID: 28634283)
J Immunother Cancer. 2020 Jun;8(1):. (PMID: 32581056)
Nat Commun. 2017 Jun 09;8:15618. (PMID: 28598415)
Front Immunol. 2019 Jul 11;10:1594. (PMID: 31354733)
Nat Commun. 2016 Feb 02;7:10391. (PMID: 26837003)
JAMA Oncol. 2018 Dec 1;4(12):1721-1728. (PMID: 30242316)
J Clin Invest. 2014 Feb;124(2):687-95. (PMID: 24382348)
Front Microbiol. 2018 Dec 17;9:3099. (PMID: 30619178)
Thorac Cancer. 2020 Jun;11(6):1621-1632. (PMID: 32329229)
J Intern Med. 2018 Feb;283(2):110-120. (PMID: 29071761)
J Cancer Res Clin Oncol. 2021 Apr;147(4):973-986. (PMID: 33550445)
N Engl J Med. 2015 May 21;372(21):2006-17. (PMID: 25891304)
Mol Ther. 2021 Feb 3;29(2):555-570. (PMID: 33038322)
Cancer Immunol Res. 2019 Dec;7(12):1910-1927. (PMID: 31597643)
Cancer Discov. 2020 Aug;10(8):1140-1157. (PMID: 32467343)
Genome Med. 2019 Jun 20;11(1):40. (PMID: 31221199)
Cancer Immunol Res. 2015 Dec;3(12):1308-15. (PMID: 26546452)
Br J Cancer. 2018 Jan;118(1):9-16. (PMID: 29319049)
Cancer Immunol Res. 2019 Oct;7(10):1700-1713. (PMID: 31387897)
Clin Cancer Res. 2017 Oct 1;23(19):5948-5958. (PMID: 28679765)
J Immunother Cancer. 2020 May;8(1):. (PMID: 32461344)
Science. 2018 Jan 5;359(6371):104-108. (PMID: 29302014)
Clin Cancer Res. 2016 Feb 15;22(4):886-94. (PMID: 26446948)
J Thorac Oncol. 2015 Jun;10(6):910-23. (PMID: 25658629)
Science. 2018 Jan 5;359(6371):97-103. (PMID: 29097493)
J Clin Invest. 2015 Nov 2;125(11):4053-62. (PMID: 26413872)
BMC Immunol. 2019 Jan 11;20(1):4. (PMID: 30634925)
JAMA Oncol. 2016 Nov 1;2(11):1403-1404. (PMID: 27490017)
Cancer Treat Rev. 2020 Jun;86:102017. (PMID: 32335505)
Science. 2015 Nov 27;350(6264):1084-9. (PMID: 26541606)
Clin Cancer Res. 2021 Feb 1;27(3):680-688. (PMID: 32958700)
Mol Oncol. 2018 Jan;12(1):3-20. (PMID: 29124875)
ESMO Open. 2019 Mar 12;4(2):e000482. (PMID: 31231559)
Clin Cancer Res. 2018 Apr 15;24(8):1816-1823. (PMID: 29549159)
Ann Oncol. 2018 Feb 1;29(2):301-310. (PMID: 29309540)
Cancer Immunol Res. 2019 Apr;7(4):630-643. (PMID: 30755403)
Br J Cancer. 2019 Nov;121(10):809-818. (PMID: 31607751)
JAMA Oncol. 2016 Sep 1;2(9):1217-22. (PMID: 27310809)
N Engl J Med. 2017 Oct 5;377(14):1345-1356. (PMID: 28889792)
N Engl J Med. 2015 Jul 2;373(1):23-34. (PMID: 26027431)
Lancet Oncol. 2016 Nov;17(11):1497-1508. (PMID: 27745820)
Nat Commun. 2017 Nov 23;8(1):1736. (PMID: 29170400)
Front Microbiol. 2020 Apr 30;11:814. (PMID: 32425919)
N Engl J Med. 2018 May 31;378(22):2078-2092. (PMID: 29658856)
Cell. 2017 Sep 7;170(6):1109-1119.e10. (PMID: 28886381)
Immunity. 2016 May 17;44(5):989-1004. (PMID: 27192565)
Integr Cancer Ther. 2019 Jan-Dec;18:1534735419880275. (PMID: 31595795)
N Engl J Med. 2015 Nov 12;373(20):1979. (PMID: 26559582)
Science. 2018 Jan 5;359(6371):91-97. (PMID: 29097494)
Sci Transl Med. 2019 Oct 23;11(515):. (PMID: 31645452)
Nat Commun. 2016 Feb 17;7:10501. (PMID: 26883990)
Cancer Res. 2014 Oct 1;74(19):5458-68. (PMID: 25274032)
Ann Oncol. 2017 Jul 1;28(7):1532-1539. (PMID: 28407039)
Oncoimmunology. 2016 Nov 4;6(1):e1253657. (PMID: 28197370)
Cancer Radiother. 2018 Oct;22(6-7):564-566. (PMID: 30170788)
N Engl J Med. 2015 Jun 25;372(26):2521-32. (PMID: 25891173)
Clin Cancer Res. 2020 Jun 15;26(12):2777-2782. (PMID: 32047000)
Cancer Immunol Immunother. 2012 Oct;61(10):1721-33. (PMID: 22406983)
J Clin Oncol. 2018 Mar 1;36(7):633-641. (PMID: 29337640)
Clin Lung Cancer. 2020 Jun 10;:. (PMID: 32778511)
Cancer Immunol Res. 2015 Apr;3(4):345-55. (PMID: 25527358)
Neoplasia. 2017 Oct;19(10):848-855. (PMID: 28923537)
Cancer Cell. 2014 Dec 8;26(6):923-937. (PMID: 25465800)
Science. 2018 Mar 23;359(6382):1350-1355. (PMID: 29567705)
Nat Med. 2018 Jun;24(6):749-757. (PMID: 29867230)
Anticancer Res. 2018 Apr;38(4):2069-2078. (PMID: 29599324)
J Exp Med. 2010 Sep 27;207(10):2187-94. (PMID: 20819927)
Ann Oncol. 2016 Mar;27(3):434-41. (PMID: 26712903)
Cancer. 2017 Dec 15;123(24):4823-4831. (PMID: 28832979)
Cancer Immunol Immunother. 2020 Jan;69(1):23-32. (PMID: 31768581)
Mol Cancer. 2018 Feb 19;17(1):38. (PMID: 29455650)
Hepatology. 2012 Oct;56(4):1342-51. (PMID: 22505239)
N Engl J Med. 2016 Sep 1;375(9):819-29. (PMID: 27433843)
Mol Ther. 2018 Oct 3;26(10):2476-2486. (PMID: 30064894)
Mol Ther Oncolytics. 2020 Nov 17;20:71-81. (PMID: 33575472)
Sci Rep. 2019 Sep 17;9(1):13455. (PMID: 31530839)
J Immunol. 2013 May 1;190(9):4899-909. (PMID: 23536636)
Immunotherapy. 2016 May;8(5):665-74. (PMID: 27140415)
Clin Cancer Res. 2013 Nov 15;19(22):6151-62. (PMID: 24030703)
Gastric Cancer. 2020 Sep;23(5):893-903. (PMID: 32180056)
J Immunol. 2005 Jun 15;174(12):7516-23. (PMID: 15944250)
Medicine (Baltimore). 2015 Feb;94(6):e515. (PMID: 25674748)
Contributed Indexing:: Keywords: oncolytic virus; cancer vaccine; molecular targeted therapy; immunotherapy; intestinal flora; Traditional Chinese Medicine
Substance Nomenclature:: 0 (B7-H1 Antigen)
0 (CD274 protein, human)
0 (Cancer Vaccines)
0 (Immune Checkpoint Inhibitors)
0 (PDCD1 protein, human)
0 (Programmed Cell Death 1 Receptor)
Entry Date(s):: Date Created: 20210324 Date Completed: 20210511 Latest Revision: 20210706
Update Code:: 20240105
PubMed Central ID:: PMC7985997
DOI:: 10.3892/mmr.2021.12001
PMID:: 33760188
: Czasopismo naukowe

Pełny tekst

Programmed cell death protein‑1 (PD‑1)/programmed death protein ligand‑1 (PD‑L1) inhibitors for treatment of a various types of cancers have revolutionized cancer immunotherapy. However, PD‑1/PD‑L1 inhibitors are associated with a low response rate and are only effective on a small number of patients with cancer. Development of an anti‑PD‑1/PD‑L1 sensitizer for improving response rate and effectiveness of immunotherapy is a challenge. The present study reviews the synergistic effects of PD‑1/PD‑L1 inhibitor with oncolytic virus, tumor vaccine, molecular targeted drugs, immunotherapy, chemotherapy, radiotherapy, intestinal flora and traditional Chinese medicine, to provide information for development of effective combination therapies.

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja